The following is a press release submitted to SOURCE media through its business wire service
***
[broadstreet zone=”53820″]
[broadstreet zone=”58610″]
MARLBOROUGH – Sunovion Pharmaceuticals Inc. (Sunovion) announced today, October 26, that the company is marking ten years since it was established in October 2010. Within a decade, Sunovion has brought forward several new treatment options to address serious medical conditions that impact the lives of millions of people worldwide.
The company’s track record has included making significant advancements in the treatment of psychiatric and neurological disorders and partnering on leading educational and advocacy initiatives to empower people living with these conditions.
[broadstreet zone=”59947″]
“For a decade, Sunovion has made substantial investments in Central Nervous System (CNS) drug discovery and successfully developed and commercialized a number of products in this space. There remains a great need for new and innovative CNS medicines,” said Antony Loebel, M.D., President and Chief Executive Officer, Sunovion Pharmaceuticals Inc. “This is an exciting time to be part of science and medicine and to enable better outcomes for patients and their care partners. At Sunovion, we are focused on improving quality of life for people living with various mental health conditions by diagnosing more accurately utilizing new technical advances and finding novel therapeutics that can change the course of illness. Over the next ten years, we expect to make further contributions to alleviate the global burden of disease.”
Sunovion’s discovery, development and commercialization of important therapies includes Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), Aptiom® (eslicarbazepine acetate) and Lonhala® Magnair® (glycopyrrolate) Inhalation Solution. The company recently announced that its newest approved therapy Kynmobi™ (apomorphine hydrochloride) sublingual film is now available in the U.S.
[broadstreet zone=”59945″]
Sunovion has a robust and expanding pipeline to address a range of psychiatric and neurologic conditions. This includes SEP-363856, which offers an innovative approach to the treatment of schizophrenia. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856.
By collaborating with patient advocacy organizations across psychiatric, neurologic and respiratory therapeutic areas, Sunovion strives to advance education and awareness of serious medical conditions. The company offers patient support and assistance through Sunovion Support® and Sunovion Answers. Sunovion Answers, which has been recognized for the third time by J.D. Power for providing an outstanding customer service experience, is designed to provide personalized assistance for patients and their caregivers and health care providers.
[broadstreet zone=”59948″]
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
Headquartered in Marlborough, Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.
MetroWest Medical Center